Simvastatin sensitizes gastric cancer to capecitabine in human gastric cancer xenografts by inhibiting NF-κB activation and abrogation of cyclin D1, cyclooxygenase-2 (COX-2), survivin, Bcl-2, CXC motif receptor 4, and MMP-9 [117]. Here, PTGS2 is linked to gastric cancer.